Literature DB >> 15111660

Efficacy and tolerability of the new antiepileptic drugs II: treatment of refractory epilepsy: report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society.

J A French1, A M Kanner, J Bautista, B Abou-Khalil, T Browne, C L Harden, W H Theodore, C Bazil, J Stern, S C Schachter, D Bergen, D Hirtz, G D Montouris, M Nespeca, B Gidal, W J Marks, W R Turk, J H Fischer, B Bourgeois, A Wilner, R E Faught, R C Sachdeo, A Beydoun, T A Glauser.   

Abstract

OBJECTIVE: To assess the evidence demonstrating efficacy, tolerability, and safety of seven new antiepileptic drugs (AEDs) (gabapentin, lamotrigine, topiramate, tiagabine, oxcarbazepine, levetiracetam, and zonisamide) in the treatment of children and adults with refractory partial and generalized epilepsies.
METHODS: A 23-member committee including general neurologists, pediatric neurologists, epileptologists, and doctors in pharmacy evaluated the available evidence based on a structured literature review including MEDLINE, Current Contents, and Cochrane library for relevant articles from 1987 until March 2003.
RESULTS: All of the new AEDs were found to be appropriate for adjunctive treatment of refractory partial seizures in adults. Gabapentin can be effective for the treatment of mixed seizure disorders, and gabapentin, lamotrigine, oxcarbazepine, and topiramate for the treatment of refractory partial seizures in children. Limited evidence suggests that lamotrigine and topiramate are also effective for adjunctive treatment of idiopathic generalized epilepsy in adults and children, as well as treatment of the Lennox Gastaut syndrome.
CONCLUSIONS: The choice of AED depends upon seizure and/or syndrome type, patient age, concomitant medications, AED tolerability, safety, and efficacy. The results of this evidence-based assessment provide guidelines for the prescription of AEDs for patients with refractory epilepsy and identify those seizure types and syndromes where more evidence is necessary.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15111660     DOI: 10.1212/01.wnl.0000123695.22623.32

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  104 in total

1.  Seizure treatment in transplant patients.

Authors:  Paul W Shepard; Erik K St Louis
Journal:  Curr Treat Options Neurol       Date:  2012-08       Impact factor: 3.598

Review 2.  Review of therapeutic options for adjuvant treatment of focal seizures in epilepsy: focus on lacosamide.

Authors:  Juan Luis Becerra; Joaquín Ojeda; Enrique Corredera; Jesús Ruiz Giménez
Journal:  CNS Drugs       Date:  2011-12-05       Impact factor: 5.749

3.  A candidate mechanism underlying the variance of interictal spike propagation.

Authors:  Helen R Sabolek; Waldemar B Swiercz; Kyle P Lillis; Sydney S Cash; Gilles Huberfeld; Grace Zhao; Linda Ste Marie; Stéphane Clemenceau; Greg Barsh; Richard Miles; Kevin J Staley
Journal:  J Neurosci       Date:  2012-02-29       Impact factor: 6.167

4.  The Art of Managing Conversions between Antiepileptic Drugs: Maximizing Patient Tolerability and Quality of Life.

Authors:  Erik K St Louis
Journal:  Pharmaceuticals (Basel)       Date:  2010-09-01

Review 5.  Management of focal-onset seizures: an update on drug treatment.

Authors:  Svein I Johannessen; Elinor Ben-Menachem
Journal:  Drugs       Date:  2006       Impact factor: 9.546

6.  AAN/AES guidelines on use of new AEDS.

Authors:  Elinor Ben-Menachem
Journal:  Epilepsy Curr       Date:  2005 Jan-Feb       Impact factor: 7.500

7.  Adopting an orphan drug: rufinamide for Lennox-Gastaut syndrome.

Authors:  Susan T Herman
Journal:  Epilepsy Curr       Date:  2009 May-Jun       Impact factor: 7.500

8.  A proposed roadmap for inpatient neurology quality indicators.

Authors:  Vanja C Douglas; S Andrew Josephson
Journal:  Neurohospitalist       Date:  2011-01

Review 9.  Zonisamide: a review of its use in the management of partial seizures in epilepsy.

Authors:  James E Frampton; Lesley J Scott
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

Review 10.  Eslicarbazepine Acetate Monotherapy: A Review in Partial-Onset Seizures.

Authors:  Matt Shirley; Sohita Dhillon
Journal:  Drugs       Date:  2016-04       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.